Newsletter Tool

Today's Rundown

Pfizer tears up gene therapy timelines, revealing a series of phase 3 delays that end vision of a banner 2022
Lynch: Aetna expects to add at least 100K members in ACA exchange plans for 2022
After a phase of slower growth, Novo Nordisk sees the fruits of its Wegovy and Rybelsus launches, CEO says
CMS finalizes fee hikes for hospital price transparency requirements
Turning CAR-T tech against solid tumors by targeting protein fragments in cancer cells
Boston Scientific wins $20M patent infringement case against Nevro over spinal cord stimulators
Merck will support Saudi Arabia effort to build biologics manufacturing operations
Heru adds 3 more diagnostics to VR headset-based vision testing platform
Incyte investigates all batches of new eczema cream Opzelura after reports of 'texture problem'
PhaseBio’s Brilinta reversal agent wins midstage test as biotech awaits key data on emergency patients
Centene selling off majority stake in U.S. Medical Management
Cara chief hands keys to former LEO head Posner, months after first approval in its 17-year history
Allara launches at-home hormone test for diagnosing polycystic ovary syndrome

Featured Story

Pfizer tears up gene therapy timelines, revealing a series of phase 3 delays that end vision of a banner 2022

By Nick Paul Taylor

Pfizer’s vision for a banner 2022 in gene therapies is over. Having previously expected to post interim data on a trio of phase 3 programs next year, Pfizer has now delayed all the readouts, setting back its plans in hemophilia and Duchenne muscular dystrophy.

Lynch: Aetna expects to add at least 100K members in ACA exchange plans for 2022

By Paige Minemyer

CVS Health beat Wall Street forecasts on both earnings and revenue for the third quarter of 2021.

After a phase of slower growth, Novo Nordisk sees the fruits of its Wegovy and Rybelsus launches, CEO says

By Eric Sagonowsky

As Novo worked to advance its suite of next-gen medicines back in 2016 and 2017, the company was in a phase of "relatively low growth," CEO Lars Fruergaard Jørgensen acknowledges. Now, thanks to new launches, things have changed.

CMS finalizes fee hikes for hospital price transparency requirements

By Paige Minemyer

Beginning Jan. 1, the Biden administration will increase the penalty for certain hospitals that are not in compliance with its price transparency requirements.

Turning CAR-T tech against solid tumors by targeting protein fragments in cancer cells

By Angus Liu

A University of Pennsylvania team has developed a new type of engineered immune cell called “peptide-centric” CAR-T that's designed to shrink solid tumors by targeting proteins inside cancer cells. CAR-T cells developed with the technology eradicated neuroblastoma in mouse models and could move into human trials in 2022 or 2023.

Boston Scientific wins $20M patent infringement case against Nevro over spinal cord stimulators

By Andrea Park

One major piece of the long-lasting and multifaceted legal battle between Boston Scientific and Nevro has finally come to a close.

Merck will support Saudi Arabia effort to build biologics manufacturing operations

By Joseph Keenan

Merck has signed on to help SaudiVax of Saudi Arabia design and construct a multimodality biologics manufacturing facility as part of the country’s efforts to provide a more localized production infrastructure for the Middle East, Northern Africa region.

Heru adds 3 more diagnostics to VR headset-based vision testing platform

By Andrea Park

After beginning the commercial launch of its re:Vive gamified vision testing platform in August, Heru has already debuted an updated version of the technology.

Incyte investigates all batches of new eczema cream Opzelura after reports of 'texture problem'

By Angus Liu

Incyte has only taken the first step in its rollout of topical atopic dermatitis drug Opzelura, but it has already hit a manufacturing problem that that threatens to derail the key launch. It has received three related complaints of texture problems related to the drug.

PM Tracker

Featured Story

Pfizer tears up gene therapy timelines, revealing a series of phase 3 delays that end vision of a banner 2022

Top Stories

Lynch: Aetna expects to add at least 100K members in ACA exchange plans for 2022

After a phase of slower growth, Novo Nordisk sees the fruits of its Wegovy and Rybelsus launches, CEO says

CMS finalizes fee hikes for hospital price transparency requirements

Turning CAR-T tech against solid tumors by targeting protein fragments in cancer cells

Boston Scientific wins $20M patent infringement case against Nevro over spinal cord stimulators

Merck will support Saudi Arabia effort to build biologics manufacturing operations

Heru adds 3 more diagnostics to VR headset-based vision testing platform

Incyte investigates all batches of new eczema cream Opzelura after reports of 'texture problem'

PhaseBio’s Brilinta reversal agent wins midstage test as biotech awaits key data on emergency patients

Centene selling off majority stake in U.S. Medical Management

Cara chief hands keys to former LEO head Posner, months after first approval in its 17-year history

Allara launches at-home hormone test for diagnosing polycystic ovary syndrome